Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy

Wang, Lifeng; Xie, Bin; Zheng, Quan; Xu, Lixia; Ye, Zhiming

doi:10.17235/reed.2020.6762/2019

Cited by 2 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even so, antiviral monotherapy has its limitations with HBV mutations, low remission rates, and long time to remission. Wang et al have previously shown in a cohort of 42 hospitalized patients with HBV-GN between the ages of 18 to 70 years that tacrolimus-entecavir combination therapy significantly reduced proteinuria without increasing the viral DNA load or causing acute renal function deterioration during combination therapy or later with entecavir monotherapy [ 57 , 58 ]. Although promising, larger studies are needed to establish this result since Wang et al used a similar regimen in two small groups with a one-year follow-up and did not find a significant difference in the proteinuria remission rates [ 59 ].…”

Section: Renal Diseasementioning

confidence: 99%

Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections

Songtanin,

Chaisrimaneepan,

Mendóza

et al. 2024

Viruses

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infections affect approximately 296 million people around the world, and the prevalence of any past or present HBV infection during the years 2015–2018 was as high as 4.3%. Acute HBV infection often presents with nonspecific symptoms and is usually self-limited, but 5% of patients can have persistent infections leading to chronic HBV infection and the risk of turning into chronic HBV infection is significantly higher in babies with vertical transmission (95%). Patients with chronic HBV infection are usually asymptomatic, but 15 to 40% of chronic HBV carriers develop cirrhosis and/or hepatocellular carcinoma. In addition to liver-related disorders, HBV is also associated with several extrahepatic complications, including glomerulonephritis, cryoglobulinemia, neurologic disorders, psychological manifestations, polyarthritis, and dermatologic disorders. Making the diagnosis of HBV can be challenging since patients with chronic infections can remain symptom-free for decades before developing cirrhosis or hepatocellular carcinoma, and patients with acute HBV infection may have only mild, nonspecific symptoms. Therefore, understanding how this virus causes extrahepatic complications can help clinicians consider this possibility in patients with diverse symptom presentations. The pathophysiology of these extrahepatic disorders likely involves immune-related tissue injury following immune complex formation and inflammatory cascades. In some cases, direct viral infection of extrahepatic tissue may cause a clinical syndrome. Currently, the American Association for the Study of Liver Diseases recommends treatment of chronic HBV infections with interferon therapy and/or nucleos(t)ide analogs, and this treatment has been reported to improve some extrahepatic disorders in some patients with chronic HBV infection. These extrahepatic complications have a significant role in disease outcomes and increase medical costs, morbidity, and mortality. Therefore, understanding the frequency and pathogenesis of these extrahepatic complications provides important information for both specialists and nonspecialists and may help clinicians identify patients at an earlier stage of their infection.

show abstract

Section: Renal Diseasementioning

confidence: 99%

Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections

Songtanin,

Chaisrimaneepan,

Mendóza

et al. 2024

Viruses

View full text Add to dashboard Cite

show abstract

“…The treatment of HBV-associated GN relies on antiviral therapy. Successful treatment with analogs (entecavir), with or without prednisolone or immune-suppressive therapies, have been reported in small series and/or case reports (73)(74)(75). Finally, diagnosis and treatment in early stage benefit patients' renal outcomes.…”

Section: Renal Manifestationsmentioning

confidence: 99%

“…In a meta-analysis from Yang et al (80) on the efficacy of NAs in patients with HBV-induced MGN, complete remission of proteinuria, total remission of proteinuria and HBeAg clearance increased significantly after antiviral therapy. In a recent study on 32 patients with HBV-MGN treated with ETV and followed for 52 weeks, complete remission of MGN and HBV replication suppression were induced (74).…”

Section: Renal Manifestationsmentioning

confidence: 99%

Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease

Cacoub

Asselah

2021

Am J Gastroenterol

View full text Add to dashboard Cite

People living with hepatitis B virus (HBV) chronic infection are exposed to high rates of liver complications including end-stage liver disease and hepatocellular carcinoma. Extrahepatic manifestations of HBV infection have long been underestimated. Several of these extrahepatic syndromes have been well described, including systemic vasculitides, glomerulonephritis, and cutaneous manifestations. Other manifestations have been more recently described such as hematological malignancies and neurological diseases. These extrahepatic manifestations are associated with significant morbidity and mortality. Although not completely understood, underlying mechanisms include HBV-induced local and systemic inflammation. Suppression of HBV replication usually improves extrahepatic manifestations. This review will discuss how HBV induces inflammation and the extrahepatic manifestations of HBV infection to guide clinical management.

show abstract

Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy

Cited by 2 publications

References 26 publications

Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections

Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections

Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease

Contact Info

Product

Resources

About